Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17200648 | 0.81 | GABRA1 (0.35) | GABRA1GABRB2 | |
| SCHEMBL17650908 | 0.81 | GABRA1 (0.33) | GABRA1GABRB2 | |
| SCHEMBL17648937 | 0.81 | GABRA1 (0.33) | GABRA1GABRB2 | |
| SCHEMBL2892526 | 0.81 | NAAA (0.31) | — | |
| SCHEMBL17649827 | 0.75 | GRM5 (0.31) | GABRA1GABRB2 | |
| SCHEMBL17649940 | 0.75 | MAPT (0.35) | GABRA1GABRB2 | |
| SCHEMBL1964508 | 0.74 | GABRA1 (0.36) | GABRA1GABRB2 | |
| SCHEMBL11555693 | 0.74 | GABRA1 (0.36) | GABRA1GABRB2 | |
| SCHEMBL11882772 | 0.70 | PLAU (0.46) | — | |
| SCHEMBL158972 | 0.69 | GABRA1 (0.46) | GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032659-B | Imidazo [1, 2-a ] imidazol-2-one derivatives for the treatment of diseases such as parkinson's disease | 豪夫迈·罗氏有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-11345708-B2 | Substituted imidazo[1,2-a]imidazoles as modulators of metabotropic glutamate receptor 4 activity | HOFFMANN-LA ROCHE INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11345708-B2 | Substituted imidazo[1,2-a]imidazoles as modulators of metabotropic glutamate receptor 4 activity | HOFFMANN-LA ROCHE INC. (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3668873-B1 | IMIDAZO[1,2-A]IMIDAZOL-2-ONE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS PARKINSON'S DISEASE | HOFFMANN LA ROCHE (CH) | 2021-06-30 | — | — | EP | disclosed |
| EP-3668873-B1 | IMIDAZO[1,2-A]IMIDAZOL-2-ONE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS PARKINSON'S DISEASE | HOFFMANN LA ROCHE (CH) | 2021-06-30 | — | — | EP | disclosed |
| US-20200291033-A1 | IMIDAZO[1,2-A]IMIDAZOL-2-ONE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS PARKINSON'S DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200291033-A1 | IMIDAZO[1,2-A]IMIDAZOL-2-ONE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS PARKINSON'S DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3668873-A1 | IMIDAZO[1,2-A]IMIDAZOL-2-ONE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS PARKINSON'S DISEASE | H. Hoffnabb-La Roche Ag (CH) | 2020-06-24 | — | — | EP | disclosed |
| CN-111032659-A | Imidazo [1, 2-a ] imidazol-2-one derivatives for the treatment of diseases such as parkinson's disease | 豪夫迈·罗氏有限公司 | 2020-04-17 | — | — | CN | disclosed |
| WO-2019034713-A1 | IMIDAZO[1,2-A]IMIDAZOL-2-ONE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS PARKINSON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034713-A1 | IMIDAZO[1,2-A]IMIDAZOL-2-ONE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS PARKINSON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345708-B2 | Substituted imidazo[1,2-a]imidazoles as modulators of metabotropic glutamate receptor 4 activity | GRM2, GRM1, GRM3 | GABRA1 105/4885GABRB2 66/4885 |
| US-20200291033-A1 | IMIDAZO[1,2-A]IMIDAZOL-2-ONE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS PARKINSON'S DISEASE | HTR2C, MC2R, GRIN2C | GABRA1 526/4885GABRB2 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.